These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 29270111)

  • 1. Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.
    Tosolini AP; Sleigh JN
    Front Mol Neurosci; 2017; 10():405. PubMed ID: 29270111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling motor neuron disease in fruit flies: Lessons from spinal muscular atrophy.
    Aquilina B; Cauchi RJ
    J Neurosci Methods; 2018 Dec; 310():3-11. PubMed ID: 29649521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
    Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K;
    Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases.
    Vidovic M; Menschikowski M; Freigang M; Lapp HS; Günther R
    Neurol Res Pract; 2024 Feb; 6(1):11. PubMed ID: 38383503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.
    Ly CV; Miller TM
    Curr Opin Neurol; 2018 Oct; 31(5):648-654. PubMed ID: 30028737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in spinal muscular atrophy therapeutics.
    Parente V; Corti S
    Ther Adv Neurol Disord; 2018; 11():1756285618754501. PubMed ID: 29434670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice.
    Perera ND; Sheean RK; Crouch PJ; White AR; Horne MK; Turner BJ
    Hum Mol Genet; 2016 Sep; 25(18):4080-4093. PubMed ID: 27466204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy.
    Cappella M; Pradat PF; Querin G; Biferi MG
    J Neuromuscul Dis; 2021; 8(1):25-38. PubMed ID: 33074186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
    Neil EE; Bisaccia EK
    J Pediatr Pharmacol Ther; 2019; 24(3):194-203. PubMed ID: 31093018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene Therapies in Motor Neuron Diseases ALS and SMA].
    Günther R
    Fortschr Neurol Psychiatr; 2023 Apr; 91(4):153-163. PubMed ID: 36822211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
    Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
    Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern approaches in gene therapy of motor neuron diseases.
    Zakharova M
    Med Res Rev; 2021 Sep; 41(5):2634-2655. PubMed ID: 32638429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-based treatment of motor neuron diseases.
    Federici T; Boulis NM
    Muscle Nerve; 2006 Mar; 33(3):302-23. PubMed ID: 16228969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
    Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease.
    Rao VK; Kapp D; Schroth M
    J Manag Care Spec Pharm; 2018 Dec; 24(12-a Suppl):S3-S16. PubMed ID: 30582825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.
    Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.